VLU Non-Inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-Layer Bandaging
11 de fevereiro de 2020 atualizado por: Tactile Medical
Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-Inferiority Study
The purpose of the study is to test non-inferiority of chronic Venous Leg Ulcer (VLU) area reduction at 16 weeks with a dual action pneumatic compression device compared to multi-layer bandaging.
Visão geral do estudo
Status
Rescindido
Condições
Intervenção / Tratamento
Descrição detalhada
Participants with a chronic venous leg ulcer will participate in a 2 week run in phase using standard of care multi-layer bandaging before being randomly assigned to either treatment using a dual action pneumatic compression device or continued multi-layer bandaging for up to 16 weeks.
Participants will be seen in clinic for treatment and evaluation of symptoms and quality of life.
Tipo de estudo
Intervencional
Inscrição (Real)
56
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85012
- Phoenix VA Health Care System
-
Phoenix, Arizona, Estados Unidos, 85015
- Associated Foot and Ankle Specialists, LLC
-
Tucson, Arizona, Estados Unidos, 85710
- Arizona Regional Medical Research
-
-
California
-
Carlsbad, California, Estados Unidos, 92009
- ILD Research Center
-
Fresno, California, Estados Unidos, 93720
- Limb Preservation Platform - Northwest
-
Fresno, California, Estados Unidos, 93721
- Limb Preservation Platform - Downtown
-
Long Beach, California, Estados Unidos, 90822
- Long Beach VA Healthcare System
-
Los Angeles, California, Estados Unidos, 90024
- UCLA Medical Center
-
Los Angeles, California, Estados Unidos, 90073
- Greater Los Angeles VA Healthcare System
-
San Diego, California, Estados Unidos, 92161
- VA San Diego Healthcare System
-
Sylmar, California, Estados Unidos, 91342
- Olive View - UCLA Medical Center
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
North Miami Beach, Florida, Estados Unidos, 33169
- Barry University Clinical Research
-
South Miami, Florida, Estados Unidos, 33143
- Foot and Ankle Institute of South Florida
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Boston Medical Center
-
-
New York
-
Stony Brook, New York, Estados Unidos, 11794
- Stony Brook University
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC School of Medicine
-
-
Ohio
-
Toledo, Ohio, Estados Unidos, 43606
- Jobst Vascular Institute
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Subject must be ≥ 18 years of age or legal age at the time of enrollment.
- Chronic venous insufficiency confirmed by ultrasound within previous 12 months or prior to randomization: if subject had bilateral CVI, the limb that possessed the largest ulcer meeting study criteria was used as the study treatment limb for evaluation and documentation throughout the study. Non-study limbs received standard of care treatment as determined by the treating clinician.
- Must have at least one of the following within the past six (6) months: Dorsalis Pedis (DP) systolic pressure ≥ 80mmHg for diabetic patients or ≥ 60mmHg for non-diabetic patients on study limb; Posterior Tibial (PT) systolic pressure ≥ 80mmHg for diabetic patients or ≥ 60mmHg for non-diabetic patients on study limb; Transcutaneous partial pressure oxygen (TcP02) > 30mmHg; Great toe systolic pressure > 40mmHg.
- Active ulceration (CEAP classification of C6): VLU was defined by open skin lesion of the leg or foot that occurred in an area affected by venous hypertension.
- Ulcer duration: Non healing VLU ≥ 1 month but not greater than 24 months.
- Ulcer size ≥ 2cm² ≤ 50cm²: if there were multiple ulcers on the study limb, the largest ulcer was used as the study treatment ulcer for evaluation and documentation throughout the study. If two ulcers were separated by no more than one centimeter of normal skin, their areas were added together for study purposes.
- Three or fewer separate full thickness ulcers on the study limb: sum of the ulcer areas on the study limb must be ≤ 50 cm².
- Leg circumferences within the following range: Ankle - 12 to 44cm; Calf - 22 to 60cm; Below knee - 22 to 68cm.
- Able and willing to provide informed consent prior to study participation.
Exclusion Criteria:
- Target ulcer or any other ulcer on the study limb involves exposure of tendon, muscle, or bone.
- Target ulcer was of non-venous etiology (sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma, malignancy).
- Treatment of the target ulcer with living cellular therapy within 30 days of the time of projected randomization.
- Endovenous ablation or other venous surgery within two weeks of enrollment: venous ultrasound must be completed after procedure to determine whether there is still venous insufficiency at the time of enrollment.
- History of skin sensitivity to any of the components of ACT, multi-layer bandages of compression garments.
- History of an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last three (3) months.
- Acute thrombophlebitis within the last six (6) weeks.
- History of pulmonary edema or decompensated congestive heart failure within six (6) weeks of screening.
- Currently has an active infection of the skin on the target limb such as cellulitis requiring antibiotics.
- History of target limb cancer within the last 2 years with the exception of treated non-melanoma skin cancer unless ulcer biopsy performed at screening is negative for neoplasia.
- Active cancer receiving chemotherapy and/or radiation therapy.
- Poorly controlled diabetes with an HbA1c value of > 12% within the past three (3) months.
- Changes to medications that affected edema within the last 30 days prior to enrollment (e.g., diuretics, calcium channel blockers of the dihyropyridine class, pioglitazone, cox-1 inhibitors, pregabalin, and gabapentin, diltiazem, or fluctuating doses of systemic steroids).
- Use of systemic corticosteroids requiring daily administration at doses greater than 5mg of Prednisone per day or equivalent for greater than 2 weeks: low dose steroid administration (Prednisone up to 5 mg per day or equivalent) was allowable for an unlimited period of time. Topical steroid administration to peri-ulcer area or other skin was allowable but could not be applied to the ulcer itself.
- Currently pregnant or trying to become pregnant.
- Inability or unwillingness to participate in all aspects of study protocol.
- Exhibited any condition which, according to the Investigator, justified the subject's exclusion from the study, such as a medical condition where an increase in venous or lymphatic return is undesirable.
- Currently participating in another clinical trial.
Additional Exclusion Criteria after two week run-in:
- Subject's target ulcer decreased in size by greater than 30% compared to the baseline area.
- Subject's target ulcer increased in size by greater than 50% compared to the baseline area.
- Subject's target ulcer measured less than 1.5cm² at the Randomization Visit.
- Subject appeared to have evidence of infection in any ulcer.
- The sum of the ulcer areas on the subject's study limb is > 50cm².
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dual Action Pneumatic Compression Device
ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
|
Dual action pneumatic compression device used to treat chronic VLUs.
Outros nomes:
|
|
Comparador Ativo: Multi-layer bandaging
PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
|
Multi-layer bandaging used to treated chronic VLUs
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of VLU Area Reduction
Prazo: Changes from Baseline to 16 weeks
|
Percentage of ulcer area reduction in the target VLU during the 16 week treatment period calculated by wound imaging software.
|
Changes from Baseline to 16 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-Reported Quality of Life
Prazo: Changes from Baseline to 16 weeks
|
The Charing Cross Venous Ulcer Questionnaire assesses the patients' perception of their health when venous ulceration is present.
All items are scored so that a lower score defines a more favorable health state (a greater reduction is associated with improved quality of life).
In addition, each item is scored using a 1 to 5 range so that the lowest and highest possible scores are 0 and 100, respectively.
|
Changes from Baseline to 16 weeks
|
|
Outpatient Costs
Prazo: Changes from Baseline to 16 weeks
|
Assessment of the effect of the Actitouch compared to a standard regimen of multi-layer bandaging on mean total outpatient costs per subject.
|
Changes from Baseline to 16 weeks
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: William Marston, MD, University of North Carolina, Chapel Hill
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de fevereiro de 2016
Conclusão Primária (Real)
1 de maio de 2017
Conclusão do estudo (Real)
1 de junho de 2017
Datas de inscrição no estudo
Enviado pela primeira vez
9 de fevereiro de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
11 de fevereiro de 2016
Primeira postagem (Estimativa)
12 de fevereiro de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
19 de fevereiro de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
11 de fevereiro de 2020
Última verificação
1 de janeiro de 2020
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 6010
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .